

# IBD Global Assessment of Patient & Physician Unmet Needs Survey

**IBD GAPPS Overview:** A global survey initiative uncovering emerging and under-recognized unmet needs for inflammatory bowel disease (IBD) patients and clinicians.



**2,398 patients<sup>1</sup>**

**~43%**

with ulcerative colitis (UC)

**~57%**

with Crohn's disease (CD)

Of the patients taking the survey, approximately 80 percent had moderate to severe disease.<sup>1,2</sup>



**654 gastroenterologists<sup>1</sup>**

## 2019 Internet-based Survey<sup>1</sup>

Overseen by a multinational steering committee of 9 gastroenterologists



Informed by patients, advocacy groups & advanced practice providers



## Important Differences Exist Between How Patients and Physicians Define Remission<sup>1</sup>

The majority of physicians defined remission through tests...<sup>1</sup>  
(67% of physicians between UC and CD)



Colonoscopies



Biopsies



Biochemical tests

...while patients (45%) most commonly defined remission as the resolution of symptoms.<sup>1</sup>



Tiredness, fatigue and/or exhaustion




Non-bloody diarrhea



Bowel movement urgency

## High Prevalence of Corticosteroid Therapy Currently in Use in IBD Management Reflects Significant Unmet Need for Additional Therapies<sup>2</sup>

Over **1/3** of IBD patients report using steroids for **4 or more** months over the past year.<sup>2</sup>



Physicians believe over **40%** of IBD patients will require 4 or more months of corticosteroids per year.<sup>2</sup>

About **1/2** of physicians express concern over patients taking corticosteroids for **4 or more months** per year.<sup>2</sup>

## Physician Satisfaction With Relatively Low IBD Remission and Durability Rates Suggests Acceptance of Sub-optimal Outcomes in Disease Control<sup>1</sup>

### 37% Remission with Current Biologics/JAKs

Physicians indicate satisfaction with results of these medications

### At Least 1-2 Years Sustained Response

Average time physicians reported satisfaction with current therapies

### 1/3 Patients Expect Disease Control of 5+ years

Most patients believe disease control is a feasible goal

1. Afzali A, et al. Patient and physician perspectives on the management of Inflammatory Bowel Disease: Disease remission and durability of treatment. Poster 482. Presented at ECCO Annual Meeting 2020.

2. Afzali A, et al. Patient and physician perspectives on the management of Inflammatory Bowel Disease: Role of steroids in the context of biologic therapy. Poster 393. Presented at ECCO Annual Meeting 2020.